November 29, 2017in Parkinson's Disease0by jvanhorn SynapCyte receives guidance from FDA to begin preclinical trials SynapCyte receives guidance from the Food and Drug Administration to begin preclinical trials in 2018 on its KS-217 patent for Parkinson’s disease.
